A randomized trial to compare the efficacy and safety of antiemetic treatment with ondansetron and ondansetron zydis in patients with breast cancer treated with high-dose epirubicin

Anticancer Research

Volumn 27, Issue 6 C, 2007, Pages 4411-4417

  Pectasides, D ^a   Dafni, U ^b   Aravantinos, G ^c   Timotheadou, E ^d   Skarlos, D V ^e   Pavlidis, N ^f   Gaglia, A ^a   Kalofonos, H P ^g   Fountzilas, G ^d  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c AGII ANARGIRI CANCER HOSPITAL   (Greece)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^e HENRY DUNANT HOSPITAL   (Greece)

^f UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^g UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

Breast cancer; Emesis; Epirubicin; Nausea; Ondansetron; Orally disintegrating tablet

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; GENERIC DRUG; METHOTREXATE; ONDANSETRON; PACLITAXEL;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BREAST CANCER; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TABLET DISINTEGRATION; TABLET FORMULATION; TREATMENT INDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; EPIRUBICIN; FEMALE; HUMANS; MIDDLE AGED; ONDANSETRON; TABLETS; VOMITING;

EID: 37549001686     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Hortobagyi GN, Frye D, Buzdar AU, Ewer MS, Fraschini G, Hug V, Ames F, Montague E, Carrasco CH, Mackay B and Benjamin RS: Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer 63(1): 37-45, 1989.
2. Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM and Tattersall MH: On the receiving end-patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19(2): 203-208, 1983.
3. Cunningham D, Hawthorn J, Pople A, Gazet JC, Ford HT, Challoner T and Coombes RC: Prevention of emesis in patients receiving cytotoxic drugs by GR 38032F, a selective 5-HT3 receptor antagonist. Lancet 1: 1461-1463, 1987.
4. Beck TM, Ciociola AA, Jones SE, Harvey WH, Tchekmedyian NS, Chang A, Galvin D and Hart NE: Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide based chemotherapy. Ann Intern Med 118: 407-413, 1993.
5. Bonneterre J, Chevallier B, Metz R, Fargeot P, Pujade-Lauraine E, Spielmann M, Tubiana-Hulin M, Paes D and Bons J: A randomized, double-blind comparison of ondansetron and metoclopromide in the prophylaxis of emesis included by cyclophosphamide, fluorouracil and doxorubicin or epirubicin chemotherapy. J Clin Oncol 8: 1063-1069, 1990.
6. Dicato MA, Kaasa S, Campora E, Bleiberg H, Warnier P, Vindevoghel A, Cunningham D, Liebhard A and Upadhyaya BK: Efficacy of twice daily versus three times daily oral ondansetron in the prevention of chemotherapy induced emesis. A randomized, single-blind multicentre study. Clin Oncol 4: 275-279, 1992.
7. Fraschini G, Ciociola A, Esparza L, Templeton D, Holmes FA, Walters RS and Hortobagyi GN: Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy. J Clin Oncol 9: 1268-1274, 1991.
8. Marschner NW, Adler M, Nagel GA, Christmann D, Fenzl E and Upadhyaya B: Double blind randomized trial of the anti-emetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide. Eur J Cancer 27: 1137-1140, 1991.
9. Seager H: Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol 50(4): 375-382, 1998.
10. Davidson N, Rapoport B, Erikstein B, L'Esperance B, Ruff P, Paska W, Miller I and Curtis P: Comparison of an orally disintegrating ondansetron tablet with the conventional ondansetron tablet for cyclophosphamide-induced emesis in cancer patients: a multicenter, double-masked study. Ondansetron Orally Disintegrating Tablet Emesis Study Group. Clin Ther 21(3): 492-502, 1999.
11. Lehoczky O, Udvary J and Pulay T: Freeze dried ondansetron: first observations with the fast dissolving oral antiemetic Zofran Zydis for the prophylaxis of the cisplatin-induced emesis in gynecological cancer patients. Neoplasma 49(2): 126-128, 2002.
12. Corapcioglu F and Sarper N: A prospective randomized trial of the antiemetic efficacy and cost-effectiveness of intravenous and orally disintegrating tablet of ondansetron in children with cancer. Pediatr Hematol Oncol 22(2): 103-114, 2005.
13. 3 receptor antagonist in the treatment of fractionated radiotherapy-induced nausea and emesis. Emesis Study Group for the Ondansetron Orally Disintegrating Tablet in Radiotherapy Treatment. Clin Oncol (R Coll Radiol) 11(5): 340-347, 1999.
14. Beck TM, York M, Chang A, Navari R, Harvey WH, Meshad M, Griffin D and Wentz A: Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. S3A-376 Study Group. Cancer Invest 15(4): 297-303, 1997.
15. Clavel M, Bonneterre J, d'Allens H and Paillarse JM: Oral ondansetron in the prevention of chemotherapy-induced emesis in breast cancer patients. French Ondansetron Study Group. Eur J Cancer 31A(1): 15-19, 1995.
16. Needles B, Miranda E, Garcia Rodriguez FM, Diaz LB, Spector J, Craig J, Cohen G, Krasnow S, Brogden J and Ames M: A multicenter, double-blind, randomized comparison of oral ondansetron 8 mg b.i.d., 24 mg q.d., and 32 mg q.d. in the prevention of nausea and vomiting associated with highly emetogenic chemotherapy. S3AA3012 Study Group. Support Care Cancer 7(5): 347-353, 1999.
17. Markman M, Kennedy A, Webster K, Peterson G, Kulp B and Belinson J: The antiemetic efficacy of oral ondansetron plus intravenous dexamethasone in patients with gynecologic malignancies receiving carboplatin-based chemotherapy. Gynecol Oncol 78(1): 43-46, 2000.
18. Herrington JD, Kwan P, Young RR, Lagow E, Lagrone L and Riggs MW: Randomized, multicenter comparison of oral granisetron and oral ondansetron for emetogenic chemotherapy. Pharmacotherapy 20(11): 1318-1323, 2000.
19. Krzakowski M, Graham E, Goedhals L, Joly F, Pawlicki M, Rapoport B, Yelle L, Lees J and McQuade B: A multicenter, double-blind comparison of i.v. and oral administration of ondansetron plus dexamethasone for acute cisplatin-induced emesis. Ondansetron Acute Emesis Study Group. Anticancer Drugs 9(7): 593-598, 1998.
20. Ariyoshi Y, Nukariya N, Akasaka Y, Suminaga M, Ota J, Ikeda M and Taguchi T: Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis]. Gan To Kagaku Ryoho 24(8): 995-1011, 1997 (in English).